Literature DB >> 15895583

ROC study of the effect of stereoscopic imaging on assessment of breast lesions.

Heang-Ping Chan1, Mitchell M Goodsitt, Mark A Helvie, Lubomir M Hadjiiski, Justin T Lydick, Marilyn A Roubidoux, Janet E Bailey, Alexis Nees, Caroline E Blane, Berkman Sahiner.   

Abstract

An observer performance study was conducted to evaluate the usefulness of assessing breast lesion characteristics with stereomammography. Stereoscopic image pairs of 158 breast biopsy tissue specimens were acquired with a GE Senographe 2000D full field digital mammography system using a 1.8x magnification geometry. A phantom-shift method equivalent to a stereo shift angle of +/- 3 degrees relative to a central axis perpendicular to the detector was used. For each specimen, two pairs of stereo images were taken at approximately orthogonal orientations. The specimens contained either a mass, microcalcifications, both, or normal tissue. Based on pathological analysis, 39.9% of the specimens were found to contain malignancy. The digital specimen radiographs were displayed on a high resolution MegaScan CRT monitor driven by a DOME stereo display board using in-house developed software. Five MQSA radiologists participated as observers. Each observer read the 316 specimen stereo image pairs in a randomized order. For each case, the observer first read the monoscopic image and entered his/her confidence ratings on the presence of microcalcifications and/or masses, margin status, BI-RADS assessment, and the likelihood of malignancy. The corresponding stereoscopic images were then displayed on the same monitor and were viewed through stereoscopic LCD glasses. The observer was free to change the ratings in every category after stereoscopic reading. The ratings of the observers were analyzed by ROC methodology. For the 5 MQSA radiologists, the average Az value for estimation of the likelihood of malignancy of the lesions improved from 0.70 for monoscopic reading to 0.72 (p=0.04) after stereoscopic reading, and the average Az value for the presence of microcalcifications improved from 0.95 to 0.96 (p=0.02). The Az value for the presence of masses improved from 0.80 to 0.82 after stereoscopic reading, but the difference fell short of statistical significance (p=0.08). The visual assessment of margin clearance was found to have very low correlation with microscopic analysis with or without stereoscopic reading. This study demonstrates the potential of using stereomammography to improve the detection and characterization of mammographic lesions.

Entities:  

Mesh:

Year:  2005        PMID: 15895583     DOI: 10.1118/1.1870172

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  6 in total

1.  Compare display schemes for lung nodule CT screening.

Authors:  Xiao Hui Wang; Janet E Durick; Amy Lu; David L Herbert; Carl R Fuhrman; Joan M Lacomis; Cynthia A Britton; Diane C Strollo; Sherry S Shang; Saraswathi K Golla; Walter F Good
Journal:  J Digit Imaging       Date:  2011-06       Impact factor: 4.056

2.  Misperceptions in Stereoscopic Displays: A Vision Science Perspective.

Authors:  Robert T Held; Martin S Banks
Journal:  ACM Trans Graph       Date:  2008-01-01       Impact factor: 5.414

3.  Quasi-continuous and discrete confidence rating scales for observer performance studies: Effects on ROC analysis.

Authors:  Lubomir Hadjiiski; Heang-Ping Chan; Berkman Sahiner; Mark A Helvie; Marilyn A Roubidoux
Journal:  Acad Radiol       Date:  2007-01       Impact factor: 3.173

Review 4.  Breast cancer imaging: a perspective for the next decade.

Authors:  Andrew Karellas; Srinivasan Vedantham
Journal:  Med Phys       Date:  2008-11       Impact factor: 4.071

5.  Human brain functional MRI and DTI visualization with virtual reality.

Authors:  Bin Chen; John Moreland; Jingyu Zhang
Journal:  Quant Imaging Med Surg       Date:  2011-12

6.  Characterization of crosstalk in stereoscopic display devices.

Authors:  Fahad Zafar; Aldo Badano
Journal:  J Soc Inf Disp       Date:  2015-05-27       Impact factor: 2.140

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.